EQT Infrastructure VI, through its indirectly owned subsidiary Otello BidCo AB, announces a recommended public offer to the shareholders of OX2 AB (publ) (“OX2”). The shares are admitted to trading on Nasdaq Stockholm, Large Cap.

OX2, founded in 2004, is a leading renewable energy platform with a large and diverse project portfolio across all major renewable energy technologies (onshore and offshore wind, solar, and storage) and is today one of the largest developers of onshore wind in Europe.

The total value of the offer is approximately SEK 16.4 billion.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Linnéa Sellström, Joel Magnusson, Lorin Arabi and Maximilian Bengtsson (apital Markets and Public M&A), Christoffer Thalin, Peter Sundgren, Filip Öhrner, Daniel Daun, Niklas Törnell and Jonatan Karlsson (Energy, M&A), Sebastian Örndahl, Hampus Peterson, Lovisa Lewin and Ebba Ehrling Sjögren (Regulatory), Kamyar Najmi (Banking and finance), Lina Österberg, Tilda Hall and Agnes Pigg (Environment and Real Estate) Sam Seddigh and Alice Göransson (Employment), Fredrika Hjelmberg and Ian Linde (IT/GDPR), Gulestan Ali (Compliance) and Julia Ulander Kull (Transaction Support Coordinator).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025